Alkermes spikes on first Phase III ALKS 5461 depression data
This article was originally published in Scrip
Executive Summary
The Alkermes drug ALKS 5461 showed rapid onset and continued improvement in major depressive disorder (MDD) in the first Phase III clinical trial for the novel, oral therapy, which was consistent with previously positive Phase II results.